Advanced in Bladder Cancer

Dr. Hamid Emamekhoo

Hematology Oncology | Hematology | Oncology
University Of Wisconsin Medical Foundation Inc
1040 Division St, 
Mauston, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Bladder Cancer
University Of Wisconsin Medical Foundation Inc
1040 Division St, 
Mauston, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hamid Emamekhoo is a Hematologist Oncology specialist and a Hematologist in Mauston, Wisconsin. Dr. Emamekhoo is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Tissue Biopsy. Dr. Emamekhoo is currently accepting new patients.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 1 clinical trial in the study of Bladder Cancer.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Stoughton Hospital
University Of Wi Hospitals & Clinics Authority
Uw Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION INC
1040 Division St, Mauston, WI 53948

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 24, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Elimusertib, Gemcitabine Hydrochloride, BAY 1895344
Study Phase: Phase 1
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: Androgen deprivation therapy, Nivolumab, Docetaxel
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Biological
Study Drugs: pTVG-HP, Nivolumab, GM-CSF
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Enrollment Status: Terminated
Publish Date: November 27, 2024
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: NIR178, PDR001
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 17, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

53 Total Publications

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Journal: Investigational new drugs
Published: August 11, 2025
Similar Doctors
Experienced in Bladder Cancer
Dr. James M. Heun
Hematology Oncology | Hematology | Oncology
Experienced in Bladder Cancer
Dr. James M. Heun
Hematology Oncology | Hematology | Oncology

Dean Health Systems Inc

250 26th St, Suite 240, 
Prairie Du Sac, WI 
 (38.0 miles away)
608-643-7899
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Heun is a Hematologist Oncology specialist and a Hematologist in Prairie Du Sac, Wisconsin. Dr. Heun is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Neuroendocrine Tumor, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

Experienced in Bladder Cancer
Dr. Adedayo A. Onitilo
Hematology Oncology | Hematology | Oncology
Experienced in Bladder Cancer
Dr. Adedayo A. Onitilo
Hematology Oncology | Hematology | Oncology

Mchs Hospitals Inc

4100 State Hwy 66, 
Stevens Point, WI 
 (58.7 miles away)
715-997-6000
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Adedayo Onitilo is a Hematologist Oncology specialist and a Hematologist in Stevens Point, Wisconsin. Dr. Onitilo is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Breast Cancer, Neuroendocrine Tumor, Colorectal Cancer, Pancreaticoduodenectomy, and Gallbladder Removal. Dr. Onitilo is currently accepting new patients.

Experienced in Bladder Cancer
Dr. Seth O. Fagbemi
Hematology Oncology | Hematology | Oncology
Experienced in Bladder Cancer
Dr. Seth O. Fagbemi
Hematology Oncology | Hematology | Oncology

Mchs Hospitals Inc

220 24th St S, Mmc River Region Wr Medi, 
Wisconsin Rapids, WI 
 (44.0 miles away)
715-424-8600
Experience:
43+ years
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients

Seth Fagbemi is a Hematologist Oncology specialist and a Hematologist in Wisconsin Rapids, Wisconsin. Dr. Fagbemi has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Inflammatory Breast Cancer, Familial Colorectal Cancer, WT1-Related Wilms Tumor Syndromes, Bone Marrow Transplant, and Prostatectomy. Dr. Fagbemi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Emamekhoo's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile